|
| US patent granted to PamGene and Tony Bartlett joins as VP marketing | | | Den Bosch, NL, June 18th 2001
PamGene, a Dutch based biotech company, today announced that the USPO granted PamGene’s patent 6,225,131. This patent describes a new method for performing flow - through microarray testing. At the same time PamGene confirmed the appointment of Tony Bartlett as Vice President Marketing.
The 6,225,131 patent describes the basis of PamGene’s special metal-oxide-based three-dimensional microarray technology and is a cornerstone in the company’s emerging patent portfolio. PamGene’s researchers have been executing a focussed research program on the use of the flow - through incubation principle for almost 6 years. The 6,225,131 patent is an additional step that will enhance PamGene’s worldwide patent protection in the general field of flow - through applications in the coming years.
The appointment of Anthony John Bartlett (40) as Vice President Marketing was announced during the seminar "Biotechnology in The Netherlands". It was organized at the occasion of the official opening of the company's product development and manufacturing site in Den Bosch, The Netherlands, during May 2001.
Anthony Bartlett "I am inspired by PamGene's entrepreneurship, the growth prospects of the PamChip™ and the team of professionals it assembled in such a short period of time." Bartlett was the Affymetrix Sales Manager for Europe, who are currently the biggest players in the field of DNA microarray testing. Bartlett was responsible for the recent increase in placements of their microarray platforms within the European region over the last two years.
Tim Kievits, founder and CEO of PamGene: "Tony brings in a wealth of commercial experience which will help us to address emerging business opportunities. We have the knowledge to advance our technology with an experienced product development team on board, but we also want to excel with the expertise in many different application areas. He can help us identify our clients' needs in order to customize our application-know-how. Having supplied the first customers with our PamChip™ systems in Europe we are now also ready to enter the US market with our systems "
About PamGene
PamGene is a biotech company that has patented technologies for a second-generation microarray platform and an expression profiling system. The PamChip™ allows faster, more accurate and cost-effective test results. The technology will be commercialized in research, pharmaceutical development, health management and industrial fields. PamGene secured a financing round of 6.4 mUSD at the end of 2000. The investors were GIMV, ALTA Partners and Life Science Partners. PamGene also recently signed a partnership with Olympus. The workforce is expected to grow to approximately 50 in 2002.
Contact
Tim Kievits, Chief Executive Officer, PamGene
Tel: +31 73 6158080
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
| |
